Jim Simons
GLUE icon

Jim Simons’s Monte Rosa Therapeutics GLUE Stock Holding History

Jim Simons’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.24M Buy
+379,100
New +$7.25M 0.01% 1235
2025
Q4 		– Sell
-395,733
Closed -$2.93M – 3425
2025
Q3 		$2.93M Sell
395,733
-219,367
-36% -$1.16M ﹤0.01% 1809
2025
Q2 		$2.77M Buy
615,100
+451,000
+275% +$2.01M ﹤0.01% 1906
2025
Q1 		$761K Sell
164,100
-81,600
-33% -$500K ﹤0.01% 2562
2024
Q4 		$1.71M Buy
245,700
+27,000
+12% +$203K ﹤0.01% 2155
2024
Q3 		$1.16M Sell
218,700
-36,014
-14% -$182K ﹤0.01% 2352
2024
Q2 		$953K Buy
254,714
+132,614
+109% +$676K ﹤0.01% 2351
2024
Q1 		$861K Buy
122,100
+16,900
+16% +$100K ﹤0.01% 2572
2023
Q4 		$594K Buy
105,200
+13,700
+15% +$53.7K ﹤0.01% 2709
2023
Q3 		$438K Buy
91,500
+9,700
+12% +$62.5K ﹤0.01% 2769
2023
Q2 		$560K Buy
81,800
+53,900
+193% +$349K ﹤0.01% 2813
2023
Q1 		$217K Buy
27,900
+11,500
+70% +$80K ﹤0.01% 3244
2022
Q4 		$125K Buy
+16,400
New +$137K ﹤0.01% 3559

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Jim Simons's GLUE Position: Q1 2026 in Review

Jim Simons opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 379,100 shares worth $6.24M. The stake represents 0.01% of the portfolio and ranks #1235 among its holdings. This is a return to the name: Jim Simons previously reported a position in GLUE as recently as Q3 2025.

Jim Simons first reported a position in GLUE in Q4 2022 and has held it in 13 quarters since. 191 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Jim Simons held 379,100 shares of Monte Rosa Therapeutics worth $6.24M as of Q1 2026.
  • Monte Rosa Therapeutics was a new Jim Simons position in Q1 2026.
  • Monte Rosa Therapeutics made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1235 holding.
  • Jim Simons first reported a position in Monte Rosa Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.